Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)

Cancer Letters

Volumn 272, Issue 1, 2008, Pages 70-76

  Moreno, María ^a   Mol, Berber M ^a   Mensdorff Pouilly, Silvia von ^a   Verheijen, René H M ^b   von Blomberg, B Mary E ^a   van den Eertwegh, Alfons J M ^a   Scheper, Rik J ^a   Bontkes, Hetty J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ADCC; Human; Invariant NKT cells; NK cells; Toll like receptor

Indexed keywords

AS 1402; CPG OLIGODEOXYNUCLEOTIDE; FLAGELLIN; IMMUNOGLOBULIN G1; PEPTIDOGLYCAN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; AGONIST; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL KILLING; CONTROLLED STUDY; HUMAN; HUMAN CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FLOW CYTOMETRY; GRANZYMES; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MUCIN-1; NATURAL KILLER T-CELLS; TOLL-LIKE RECEPTORS;

EID: 53949098954     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.06.028     Document Type: Article

References (25)

1. Ho S.B., Niehans G.A., Lyftogt C., Yan P.S., Cherwitz D.L., Gum E.T., Dahiya R., and Kim Y.S. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 53 (1993) 641-651
2. Karsten U., von Mensdorff-Pouilly S., and Goletz S. What makes MUC1 a tumor antigen?. Tumour Biol. 26 (2005) 217-220
3. Verhoeyen M.E., Saunders J.A., Price M.R., Marugg J.D., Briggs S., Broderick E.L., Eida S.J., Mooren A.T., and Badley R.A. Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. Immunology 78 (1993) 364-370
4. Snijdewint F.G., von Mensdorff-Pouilly S., Karuntu-Wanamarta A.H., Verstraeten A.A., Livingston P.O., Hilgers J., and Kenemans P. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int. J. Cancer 93 (2001) 97-106
5. Moreno M., Bontkes H.J., Scheper R.J., Kenemans P., Verheijen R.H.M., and Von Mensdorff-Pouilly S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 257 (2007) 47-55
6. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: facts, functions and fallacies. Immunol. Today 21 (2000) 573-583
7. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
8. Takeda K., and Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17 (2005) 1-14
9. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., and Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168 (2002) 4531-4537
10. Lauzon N.M., Mian F., MacKenzie R., and Ashkar A.A. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell. Immunol. 241 (2006) 102-112
11. Gorski K.S., Waller E.L., Bjornton-Severson J., Hanten J.A., Riter C.L., Kieper W.C., Gorden K.B., Miller J.S., Vasilakos J.P., Tomai M.A., and Alkan S.S. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int. Immunol. 18 (2006) 1115-1126
12. Hart O.M., thie-Morales V., O'Connor G.M., and Gardiner C.M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-γ production. J. Immunol. 175 (2005) 1636-1642
13. Sivori S., Falco M., Della C.M., Carlomagno S., Vitale M., Moretta L., and Moretta A. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. USA 101 (2004) 10116-10121
14. Marschner A., Rothenfusser S., Hornung V., Prell D., Krug A., Kerkmann M., Wellisch D., Poeck H., Greinacher A., Giese T., Endres S., and Hartmann G. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur. J. Immunol. 35 (2005) 2347-2357
15. Montoya C.J., Jie H.B., Al-Harthi L., Mulder C., Patino P.J., Rugeles M.T., Krieg A.M., Landay A.L., and Wilson S.B. Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J. Immunol. 177 (2006) 1028-1039
16. Metelitsa L.S., Naidenko O.V., Kant A., Wu H.W., Loza M.J., Perussia B., Kronenberg M., and Seeger R.C. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167 (2001) 3114-3122
17. Roda J.M., Parihar R., and Carson III W.E. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J. Immunol. 175 (2005) 1619-1627
18. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198 (2003) 267-279
19. Wooldridge J.E., Ballas Z., Krieg A.M., and Weiner G.J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89 (1997) 2994-2998
20. van Ojik H.H., Bevaart L., Dahle C.E., Bakker A., Jansen M.J., van Vugt M.J., van de Winkel J.G., and Weiner G.J. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 63 (2003) 5595-5600
21. Leonard J.P., Link B.K., Emmanouilides C., Gregory S.A., Weisdorf D., Andrey J., Hainsworth J., Sparano J.A., Tsai D.E., Horning S., Krieg A.M., and Weiner G.J. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res. 13 (2007) 6168-6174
22. Mark K.E., Corey L., Meng T.C., Magaret A.S., Huang M.L., Selke S., Slade H.B., Tyring S.K., Warren T., Sacks S.L., Leone P., Bergland V.A., and Wald A. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195 (2007) 1324-1331
23. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., and Presta L.G. High resolution mapping of the binding site on human IgG1 for Fc γ RI, Fc γ RII, Fc γ RIII, and FcRn and design of IgG1 variants with improved binding to the Fc γ R. J. Biol. Chem. 276 (2001) 6591-6604
24. M. Moreno, J.W. Molling, S. von Mensdorff-Pouilly, R.H.M. Verheijen, B.M.E. von Blomberg, A.J.M. van den Eertwegh, R.J. Scheper, H.J. Bontkes, In vitro expanded human iNKT cells promote NK cell functional activity, Clin. Immunol. (2008) in press.
25. M. Moreno, B.M. Mol, S. von Mensdorff-Pouilly, R.H.M. Verheijen, E.C. de Jong, B.M.E. von Blomberg, A.J.M. van den Eertwegh, R.J. Scheper, H.J. Bontkes, Differential indirect activation of human invariant NKT cells by Toll-like receptor (TLR) agonists, Submitted for publication.